期刊文献+

叶酸联合维生素B_(12)与二甲双胍对2型糖尿病患者的疗效分析

Analysis of Folic Acid Combined with Vitamin B_(12)Plus Metformin in the Treatment of Patients with Type 2 Diabetes Mellitus
下载PDF
导出
摘要 目的:探讨叶酸联合维生素B_(12)(VB_(12))与二甲双胍治疗2型糖尿病(T2DM)患者的临床疗效。方法:选取2019年2月~2021年3月某院收治的112例T2DM患者作为研究对象,采用随机数字表法分为对照组(VB_(12)+二甲双胍,n=56)和观察组(叶酸+VB_(12)+二甲双胍,n=56)。对比两组患者血糖[空腹血糖(FBG)、餐后2h血糖(2hBG)]、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、稳态模型胰岛素抵抗指数(HOMA-IR)和同型半胱氨酸(Hcy)水平以及Th1、Th17、Th1/Th17,并比较两组临床疗效、不良反应及并发症发生情况。结果:治疗后,两组患者FBG、2hBG、HO-MA-IR、HbA1c、FINS和Hcy均低于治疗前,且观察组低于对照组(P<0.05);Th1和Th17水平低于治疗前,且观察组低于对照组(P<0.05);Th1/Th17高于治疗前,且观察组高于对照组(P<0.05)。观察组临床治疗总有效率高于对照组(P<0.05);两组患者不良反应发生率比较无统计学差异(P>0.05);观察组的并发症发生率低于对照组(P<0.05)。结论:叶酸联合VB_(12)与二甲双胍治疗T2DM患者的疗效确切,可有效调节Th1/Th17平衡,改善血糖、胰岛素水平,安全性较高。 Objective:To investigate the therapeutic effect of folic acid combined with vitamin B_(12)(VB_(12))and metformin in patients with type 2 diabetes mellitus(T2DM).Methods:112 T2DM patients admitted to a certain hospital from February 2019 to March 2021 were selected as the study subjects.They were randomly divided into a control group(VB_(12)+metformin,n=56)and an observation group(folic acid+VB_(12)+metformin,n=56)using a random number table method.The blood glucose levels[fasting blood glucose(FBG),2-hour postprandial blood glucose(2hBG)],glycated hemoglobin(HbA1c),fasting insulin(FINS),homeostasis model assessment-insulin resistance(HOMA-IR),homocysteine(Hcy),as well as Th1,Th17,Th1/Th17 levels were compared between the two groups.And compare the clinical efficacy,adverse reactions,and incidence of complications between the two groups.Results:After treatment,the FBG,2hBG,HOMA-IR,HbA1c,FINS,and Hcy of both groups of patients were lower than before treatment,and were lower in the observation group than those in the control group(P<0.05);the levels of Th1 and Th17 were lower than before treatment,and were lower in the observation group was lower than those in the control group(P<0.05);Th1/Th17 was higher than before treatment,and was higher in the observation group was higher than that in the control group(P<0.05).The total effective rate of clinical treatment in the observation group was higher than that in the control group(P<0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05);the incidence of complications in the observation group was lower than that in the control group(P<0.05).Conclusion:Combination of folic acid with VB_(12)and metformin has a definite therapeutic effect on T2DM patients,which can effectively regulate Th1/Th17 balance,improve blood glucose and insulin levels,and has high safety.
作者 王昱 张红瑾 姬劲锐 WANG Yu;ZHANG Hong-jin;JI Jin-rui(Department of General Medicine,Nanyang Central Hospital,Nanyang 473009,China;Department of Endocrinology,Nanyang Central Hospital,Nanyang 473009,China;People's Hospital of Zhengzhou,Zhengzhou 450000,China)
出处 《中国合理用药探索》 CAS 2024年第6期1-6,共6页 Chinese Journal of Rational Drug Use
基金 2019年度河南省医学科技攻关计划(联合共建)项目(LHGJ20191068)。
关键词 叶酸 维生素B_(12) 二甲双胍 2型糖尿病 胰岛素抵抗 folic acid vitamin B_(12) metformin type 2 diabetes mellitus insulin resistance
  • 相关文献

参考文献12

二级参考文献76

  • 1孙明谨,曾玉琴,李雪锋,朱大菊.糖尿病患者T,B细胞亚群的研究[J].中国现代医学杂志,2005,15(22):3455-3457. 被引量:30
  • 2Derosa G. Cicerc~ AF, D' Ange]o A, et al. Telmisartan and irbe sartan therapy in type 2 diabetic patients treated with rosighta- zone: effects on insulin-resistance, leptin and tumour necrosis fac- tor alpha[J]. Hypertens Res, 2006,29 ( 11 ) : 849-856.
  • 3Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker[J]. Best Pract Res Clin Endocrinol Metab, 2014,28(1) : 119-130.
  • 4Cinar N, Gurlek A. Association between novel adipocytokines ad- iponectin, vaspin, visfatin, and thyroid= an experimental and clinical update[J]. Endocr Connect,2013,2(4) :R30-38.
  • 5Mangge H, Almer G, Truschnig Wilders M, eta[. Inflamma- tion, adiponectin, obesity and cardiovascular risk [J]. Curr Med Chem,2010,17(36) :4511-4520.
  • 6Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinmia in obesity and type 2 diabetes close association with insulin resist- ance and hyperinsulinemia[J].J Clin Endocrinol Metab, 2001,86 (5) : 1930-1935.
  • 7Wallace TM, Levy JC, Matthews DR. Use and abuse of H()MA modeling[J]. Diabetes Care, 2004,27 (6) : 1487-1495.
  • 8Matthews DR. lnsulin resistance and beta-cell function: a clinical perspective[J]. Diabetes ()bes Metab, 2001,3 (Suppl 1 ) : $28-33.
  • 9Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myo- cardial infarction and deatb from cardiovascular causes[J].N Engl J Med,2007,356(24) :2457-2471.
  • 10Bahadir O, Uzunlulu M, (/guz A, et al. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome[J]. Hypertens Res,2007,30( 1 ):49-53.

共引文献5361

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部